Figure 2.

Non-total therapy (non-TT) overall survival (a) and event-free survival (b) from first transplant according to the presence of cytogenetic abnormalities (CA) detected at baseline or pre-transplant. Outcomes were superior in the absence of CA at both time points, followed by an intermediate prognosis in patients with CA detected only at baseline whereas those with detectable CA pre-transplant had the poorest outcomes regardless of CA presence at baseline.